All conditions

Primary Biliary Cholangitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

271
Trials on record
53
Recruiting now
3
Australian sites
12
Phase 3 trials
3
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Primary Biliary Cholangitis →

Get alerts when Primary Biliary Cholangitis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Primary Biliary Cholangitis (PBC)

Primary Biliary Cholangitis, or PBC, is a long-term liver condition where the immune system mistakenly attacks the small bile ducts inside the liver. Bile ducts are tiny tubes that carry bile, a digestive fluid, out of the liver. When these ducts become damaged and inflamed over time, bile builds up inside the liver, which can gradually cause scarring. It is considered an autoimmune condition, meaning the body's own defence system is working against healthy tissue rather than a harmful invader. Many people live with PBC for years with relatively mild symptoms, though experiences can vary widely from person to person.

In Australia, PBC affects roughly 1 in 1,000 women over the age of 40, though it can also occur in men and younger adults. It is diagnosed far more often in women, and there appears to be a genetic component, meaning it can sometimes run in families. Because symptoms in the early stages can be subtle — such as fatigue or itchy skin — many people are diagnosed through routine blood tests before they notice anything significant. Australian gastroenterologists and hepatologists (liver specialists) are well familiar with the condition, and specialist care is available through major hospitals and liver clinics around the country.

Treatment for PBC has improved considerably over recent decades. The general approach focuses on slowing the progression of liver damage and managing symptoms like itching and fatigue. Regular monitoring through blood tests and imaging is typically an important part of ongoing care. Dietary and lifestyle considerations are often discussed as part of managing overall liver health. If you have questions about what your diagnosis means for you personally, your specialist or GP is the best person to speak with, and organisations like the Liver Foundation of Australia can also provide helpful support and information.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Primary Biliary Cholangitis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Primary Biliary Cholangitis

3 medicines listed on the PBS for Primary Biliary Cholangitis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 3 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Elafibranor Iqirvo Primary biliary cholangitis (previously known as Primary biliary cirrhosis) AU$5722.2 Authority required
Obeticholic acid Ocaliva Primary biliary cholangitis (previously known as Primary biliary cirrhosis) AU$3631 Authority required
Ursodeoxycholic acid Ursofalk, Ursodox GH Primary biliary cholangitis (previously known as Primary biliary cirrhosis) AU$97.13 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Primary Biliary Cholangitis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Primary Biliary Cholangitis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Primary Biliary Cholangitis by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

Clinical trials for Primary Biliary Cholangitis

Showing 124 of 124 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01473524 · Intercept Pharmaceuticals Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 1 December 2013
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL +5 more

**Who might be able to join this trial:** - You have been diagnosed with, or are likely to have, a liver condition called Primary Biliary Cholangitis (PBC), shown by at least 2 of these 3 things: abnormal liver enzyme (ALP) levels for at least 6 months, a positive blood test for certain antibodies linked to PBC, or a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02966834 · GlaxoSmithKline Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 15 April 2020
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇵🇱 PL🇪🇸 ES +2 more

**Who might be able to join this trial:** - People aged 18 to 80 years old at the time of signing the consent form. - People who have a confirmed diagnosis of Primary Biliary Cholangitis (PBC), shown by at least 2 of the following: a history of certain abnormal liver blood test results (raised ALP levels) first notice...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03394924 · Enanta Pharmaceuticals, Inc Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 19 December 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇳🇱 NL🇪🇸 ES +2 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender or ethnic background) - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least two specific medical tests or results - If you have not had a liver biopsy in the last 2 yea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03602560 · Gilead Sciences Phase 3 · 23 countries Completed
Completed Phase 3 Est. completion 16 February 2020
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇫🇷 FR🇩🇪 DE +15 more

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You are between 18 and 75 years old - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least two of the following: abnormal liver enzyme levels for at least 6...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04480840 · Pliant Therapeutics, Inc. Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 26 February 2024
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇳🇱 NL🇬🇧 GB +1 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of bile duct disease called large duct PSC, confirmed by a specialist imaging scan of the bile ducts - There is evidence of some liver scarring (fibrosis), shown by a scan, a blood test score, or a previous liver biopsy — but not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04620733 · Gilead Sciences Phase 3 · 26 countries Completed
Completed Phase 3 Est. completion 11 August 2023
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇿 CZ🇩🇰 DK +18 more

**Who might be able to join this trial:** - People who have given written consent to participate, as required by local laws. - People who have received a confirmed diagnosis of primary biliary cholangitis (PBC), a liver condition. - People who have been taking a medication called ursodeoxycholic acid (UDCA) for at lea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05014672 · Calliditas Therapeutics Suisse SA Phase 2 · 18 countries Completed
Completed Phase 2 Est. completion 31 May 2024
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

**Who might be able to join this trial:** - Adults aged 18 or older at the time of agreeing to participate. - People who are willing and able to sign a consent form and follow the study requirements. - People who have a confirmed or probable diagnosis of Primary Biliary Cholangitis (PBC), shown by at least 2 of the fo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06016842 · Ipsen Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 31 May 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇿 CZ +18 more

**Who might be able to join this trial:** - You must be 18 years of age or older at the time you sign the consent form - You must have a confirmed or probable diagnosis of primary biliary cholangitis (PBC), which is a liver condition caused by damage to the bile ducts - You must have cirrhosis (scarring of the liver)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06051617 · Gilead Sciences Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2030
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇿 CZ +20 more

**Who might be able to join this trial:** - You must be at least 18 years old. - You must have a confirmed diagnosis of a liver condition called Primary Biliary Cholangitis (PBC). - You must have evidence of scarring of the liver (cirrhosis). - Your liver condition must be rated as either "Child-Pugh A" or "Child-Pugh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06447168 · Ipsen Not Applicable · 10 countries Recruiting
Recruiting Not Applicable Est. completion 15 July 2032
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇪 DE🇬🇷 GR🇮🇹 IT🇪🇸 ES🇦🇪 AE +2 more

**Who might be able to join this trial:** - You have agreed in writing to take part and are willing to follow the study's rules and procedures. - You have been diagnosed with PBC (Primary Biliary Cholangitis), a condition affecting the liver. - Your doctor has decided you should start taking a medication called elafibr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT02308111 · Intercept Pharmaceuticals Phase 4 · 31 countries Terminated
Terminated Phase 4 Est. completion 23 December 2021
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +23 more

**Who might be able to join this trial:** - You have been diagnosed with, or are likely to have, a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of the following: abnormal liver enzyme (alkaline phosphatase) levels for at least 6 months, a positive blood test for certain antibodies...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03155932 · Arena Pharmaceuticals Phase 2 · 3 countries Terminated
Terminated Phase 2 Est. completion 31 January 2019
🇦🇺 AU🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old (inclusive) - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least 2 of the following: a specific blood test showing certain antibodies, a liver enzyme (ALP) that has been above a certain level for at least...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03633227 · Intercept Pharmaceuticals Phase 4 · 12 countries Terminated
Terminated Phase 4 Est. completion 9 July 2021
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇪🇪 EE🇩🇪 DE🇭🇺 HU +4 more

**Who might be able to join this trial:** - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: abnormal liver enzyme (ALP) levels for 6+ months, a positive blood antibody test linked to PBC, or a liver biopsy showing PBC. - You have cirrhosis (scarring of the liv...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03890120 · Gilead Sciences Phase 3 · 16 countries Terminated
Terminated Phase 3 Est. completion 10 November 2022
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇮 FI🇫🇷 FR🇩🇪 DE +8 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of bile duct condition called large duct PSC (primary sclerosing cholangitis) - A liver biopsy taken during the screening process shows an acceptable sample with scarring rated at a low-to-moderate level (stage F0 to F3, meaning n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04594694 · Intercept Pharmaceuticals Phase 2 · 17 countries Terminated
Terminated Phase 2 Est. completion 14 October 2025
🇦🇺 AU🇧🇪 BE🇭🇷 HR🇨🇿 CZ🇪🇪 EE🇫🇷 FR🇩🇪 DE🇬🇷 GR +9 more

Who might be able to join this trial: - You have been diagnosed with a condition called PBC (Primary Biliary Cholangitis), either confirmed or considered likely by your doctor - Your blood tests show certain elevated liver values (specifically ALP and/or bilirubin) that meet the trial's requirements - You have either b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06488911 · Intercept Pharmaceuticals Phase 3 · 21 countries Terminated
Terminated Phase 3 Est. completion 21 October 2025
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇭🇷 HR🇨🇿 CZ🇪🇪 EE🇫🇷 FR +13 more

Who might be able to join this trial: - You must have a condition called PBC (Primary Biliary Cholangitis) and must currently be taking the study medication as part of a previous related trial called Study 747-213 or Study 747-214. Who may not be able to join: - You have, or have had, other liver diseases alongside yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04526665 · Ipsen Phase 3 · 14 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 1 June 2023
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇫🇷 FR🇩🇪 DE🇮🇹 IT +6 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with Primary Biliary Cholangitis (PBC), either confirmed or probable - Your blood test shows a liver enzyme called alkaline phosphatase (ALP) is at least 1.67 times above the normal upper limit - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00570765 · Intercept Pharmaceuticals Phase 2 · 7 countries Completed
Completed Phase 2 Est. completion 21 September 2010
🇦🇹 AT🇨🇦 CA🇫🇷 FR🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Women who are past menopause, have had surgery to prevent pregnancy, or (if still able to become pregnant) are willing to use an effective form of contraception throughout the study and for 14 days after finishing the medication. - Men who are willing to use an effective form...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00575042 · University of Florida Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 August 2009
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Biliary Cirrhosis (PBC), confirmed by a blood test (positive antimitochondrial antibodies) and/or a liver biopsy - You have previously been treated with a medication called UDCA at a dose of 13–15 mg/kg per day for at least 1 year - Your b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01085760 · Mayo Clinic Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 1 November 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), shown by abnormal liver blood test results that have been elevated for at least 6 months. - A special imaging test of your bile ducts (such as an ERCP or MRCP) has shown blockages, narrowing, or irregular sha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01249092 · The Cleveland Clinic Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 June 2012
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 76 years old (male or female). - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least three of the following: a positive blood test for certain antibodies (AMA), abnormal liver-related blood test results, a liver biopsy cons...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01322386 · Stanford University Phase 1 Completed
Completed Phase 1 Est. completion 1 October 2010

Who might be able to join this trial: - You have been diagnosed with biliary atresia (a liver condition affecting bile ducts, usually in infants) or primary sclerosing cholangitis (a disease causing scarring and narrowing of the bile ducts) - You are a healthy comparison participant who is already scheduled to have a c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01389973 · Janssen Research & Development, LLC Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 1 June 2013
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with, or are likely to have, a liver condition called Primary Biliary Cirrhosis (PBC) - You have been taking a stable dose of a medication called ursodeoxycholic acid for at least 6 months before the start of the trial - A specific liver enzyme in your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01672853 · Gilead Sciences Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 8 August 2016
🇧🇪 BE🇨🇦 CA🇩🇰 DK🇩🇪 DE🇮🇹 IT🇳🇱 NL🇪🇸 ES🇸🇪 SE +2 more

**Who might be able to join this trial:** - You are between 18 and 70 years old and have been diagnosed with a chronic (long-term) liver condition affecting bile flow for at least 6 months - Your liver biopsy results (if done within the last 3 months) or a new biopsy are consistent with a condition called Primary Scle...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01802073 · Stanford University Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 1 August 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Sclerosing Cholangitis (PSC), confirmed by a liver biopsy and/or imaging scans. - You have had a colonoscopy within the past year, or are willing to have one at the start of the study. - You either have a bowel con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01865812 · Intercept Pharmaceuticals Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 13 August 2014
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with, or are likely to have, a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: abnormal liver enzyme levels in blood tests for at least 6 months, a positive result on a specific blood antibody test,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01879735 · University of Aarhus Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 1 September 2014
🇩🇰 DK

Who might be able to join this trial: - People who have a liver condition that affects the flow of bile (a cholestatic disorder) - Healthy individuals with no such condition may also be able to take part Who may not be able to join: - People who weigh more than 110 kg (about 243 pounds), as this can make a medical pro...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01904058 · Mirum Pharmaceuticals, Inc. Phase 2 · 3 countries Completed
Completed Phase 2 Est. completion 1 April 2015
🇨🇦 CA🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Primary Biliary Cirrhosis (a liver condition) - You experience moderate to severe itching related to your condition - You have been taking a medication called ursodeoxycholic acid (UDCA) for at least 6 months, or you are unable to take this medication...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02061540 · Mirum Pharmaceuticals, Inc. Phase 2 · 3 countries Completed
Completed Phase 2 Est. completion 1 February 2016
🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old (inclusive) - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition affecting the bile ducts - If you have inflammatory bowel disease (IBD), your symptoms are currently mild to moderate at most, based on your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02078882 · Christopher Bowlus, MD Phase 4 · 1 country Completed
Completed Phase 4 Est. completion 1 October 2018
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least 2 of the following 3 things: a specific blood test result (AMA titer above 1:40), a liver enzyme called alkaline phosphatase that has been higher than normal for at least 6 months, or a live...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02424175 · Brigham and Women's Hospital Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 30 August 2017
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have a confirmed diagnosis of Primary Sclerosing Cholangitis (PSC) — a liver condition — along with a diagnosis of inflammatory bowel disease - Your liver condition has been present for more than 6 months and has been confirmed by specif...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02516605 · Novartis Pharmaceuticals Phase 2 · 6 countries Completed
Completed Phase 2 Est. completion 2 August 2018
🇨🇦 CA🇩🇪 DE🇵🇱 PL🇷🇺 RU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: a liver enzyme called ALP being higher than normal for at least 6 months; a positive blood test for certain antibodies link...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02653625 · Tobira Therapeutics, Inc. Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 31 August 2017
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a chronic liver condition that affects bile flow (cholestatic liver disease) lasting at least 6 months. - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), confirmed by a specific type of scan (MRCP or ERCP) showing scarring of t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02704364 · NGM Biopharmaceuticals, Inc Phase 2 · 4 countries Completed
Completed Phase 2 Est. completion 1 June 2017
🇫🇷 FR🇳🇱 NL🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a condition called Primary Sclerosing Cholangitis (PSC), which is a disease that causes scarring and narrowing of the bile ducts in the liver. Who may not be able to join: - You have a significant liver disease caused by something other than PSC. - Y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02943460 · Gilead Sciences Phase 2 · 4 countries Completed
Completed Phase 2 Est. completion 28 February 2018
🇦🇹 AT🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), confirmed by a special imaging scan of your bile ducts within the past 12 months - A specific liver enzyme in your blood called alkaline phosphatase (ALP) is above a certain elevated level - If you take a med...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02978339 · John E. Eaton Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 16 November 2018
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with primary sclerosing cholangitis (PSC), a condition that causes scarring and narrowing of the bile ducts in and/or outside the liver. - Your blood test has shown a raised liver enzyme called alkaline phosphatase (at least 1.5 times the upper normal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03112681 · Zydus Therapeutics Inc. Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 7 August 2020
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 to 75 years (male or female) may be considered for this trial. - People who have been taking a medicine called Ursodeoxycholic acid (UDCA) at a stable, prescribed dose for at least 12 months (with no dose changes in the last 3 months) may be considered, OR peo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03124108 · Genfit Phase 2 · 5 countries Completed
Completed Phase 2 Est. completion 31 October 2018
🇫🇷 FR🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You have been diagnosed with, or are likely to have, a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: abnormal liver enzyme (ALP) levels...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03333928 · HighTide Biopharma Pty Ltd Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 30 April 2020
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition involving blocked or scarred bile ducts, confirmed by a specific scan (MRCP or ERCP) and present for more than 6 months - Your blood tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03545672 · RenJi Hospital Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 15 August 2019
🇨🇳 CN

**Who might be able to join this trial:** *For people with Primary Biliary Cholangitis (PBC):* - You are between 18 and 80 years old - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least two of the following: a history of abnormal liver enzyme levels in blood...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03722576 · Elizabeth Carey Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 30 June 2020
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with a liver condition called Primary Sclerosing Cholangitis (PSC), confirmed by specific blood tests and imaging of your bile ducts - Your blood test shows a certain liver enzyme (called ALP) is at least 1.5 time...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04053023 · GlaxoSmithKline Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 25 November 2019
🇬🇧 GB

**Who might be able to join this trial:** - People aged between 18 and 80 years old at the time of signing the consent form - People considered generally healthy by the study doctor, based on a medical check-up including health history, physical examination, vital signs, blood tests, and a heart tracing (ECG) - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04604652 · HighTide Biopharma Pty Ltd Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 31 May 2022
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least two of the following: abnormal liver enzyme levels in your blood, a positive blood test for a specific antibody (AMA), or a liver biopsy showing a particular patter...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04950127 · GlaxoSmithKline Phase 3 · 2 countries Completed
Completed Phase 3 Est. completion 28 October 2024
🇩🇪 DE🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 80 years old (inclusive) at the time of signing the consent form - You have been diagnosed with Primary Biliary Cholangitis (PBC), a liver condition (confirm with trial site if unsure about your diagnosis) - You experience moderate to severe itching rel...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05292872 · Intercept Pharmaceuticals Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 31 December 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a condition called Primary Biliary Cholangitis (PBC), either confirmed or strongly suspected - You have either not responded well enough to a medication called UDCA (ursodeoxycholic acid), or you were unable to tolerate it - You are 18 years old o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05525520 · Escient Pharmaceuticals, Inc Phase 2 · 8 countries Completed
Completed Phase 2 Est. completion 17 July 2024
🇧🇪 BE🇨🇦 CA🇫🇷 FR🇮🇱 IL🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are between 18 and 80 years old - You have been diagnosed with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), which are chronic liver conditions - You experience moderate to severe itching (pruritus) on a consistent basis related to your liver cond...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06061341 · Washington University School of Medicine Not Applicable · 1 country By Invitation
By Invitation Not Applicable Est. completion 1 November 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are currently on the waiting list for a liver transplant, or you received a liver transplant within the last 30 days - Your liver transplant is needed because of one of these conditions: autoimmune hepatitis (AIH), Primary Biliary Cirrhosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06591468 · Han Ying Phase 3 · 1 country By Invitation
By Invitation Phase 3 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and are able to understand and sign a consent form - You are between 18 and 75 years old - You have been diagnosed with primary biliary cholangitis (PBC) based on recognised international guidelines, confirmed by at least two of the f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07631442 · Stanford University Not Applicable · 1 country By Invitation
By Invitation Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Biliary Cholangitis (PBC), a liver condition, based on at least 2 of the following 3 things: abnormal liver blood test results (specifically certain enzyme levels), a positive result on certain autoimmune blood tests, or a liver biopsy tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05462093 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 July 2028

Who might be able to join this trial: - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition affecting the bile ducts, confirmed using standard medical guidelines - You are 18 years old or older - You are able to understand and agree to take part in the study by giving your consent Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06733519 · Tharimmune Inc Phase 2 Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 1 March 2027

**Who might be able to join this trial:** - Adults between 18 and 75 years old (men or women) at the time of signing the consent form. - People diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least 2 of the following: a long-term history of raised liver enzyme levels (for at least 6 months), certain...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06886360 · Dr. Falk Pharma GmbH Phase 3 Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 1 September 2027

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the study. - You must be 18 years old or older (any gender). - You must have previously been diagnosed with PSC (Primary Sclerosing Cholangitis), have taken part in an earlier related trial called NUC-5/...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06975150 · CuromeBiosciences Phase 2 Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 30 August 2028

**Who might be able to join this trial:** - You are 18 years old or older - You are willing to use at least one reliable form of birth control (such as hormonal contraceptives, an IUD, a double-barrier method, or surgical sterilization) during the study and for 30 days after your last dose — or you are a woman who has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07122206 · Methodist Health System Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 August 2027

**Who might be able to join this trial:** - You have been officially diagnosed with Primary Biliary Cholangitis (PBC), a liver condition. - You are 18 years of age or older. - You are currently taking a medication called ursodiol (also known as ursodeoxycholic acid) for PBC, or you cannot tolerate this medication due t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07319169 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 January 2028
🇧🇪 BE

Who might be able to join this trial: - You are 18 years old or older - You are seen as an outpatient (not staying overnight in hospital) at UZ Brussels - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by specific blood tests and/or a liver biopsy - You are currently being treated with ursode...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07341282 · McMaster University Phase 2 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older - You have been formally diagnosed with both ulcerative colitis (a type of inflammatory bowel disease) and a liver condition called primary sclerosing cholangitis (PSC) - Your ulcerative colitis is currently rated as moderate to severe, based...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07424677 · Zydus Therapeutics Inc. Phase 3 Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 1 July 2028

Who might be able to join this trial: - You are between 18 and 80 years old (inclusive) - You have been officially diagnosed with Primary Biliary Cholangitis (a liver condition) - You have been taking a medication called ursodeoxycholic acid for at least 12 months at a stable dose for at least 6 months before your firs...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07477782 · Assistance Publique - Hôpitaux de Paris Phase 2 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 1 April 2029
🇫🇷 FR

Who might be able to join this trial: - You are a man or woman aged between 18 and 75 years old - You have been diagnosed with a type of primary sclerosing cholangitis (PSC) affecting the larger bile ducts, confirmed by a specific imaging scan or procedure of the bile ducts - You have been diagnosed with inflammatory b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07549607 · University of Leipzig Not Applicable · 2 countries Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 April 2028
🇩🇪 DE🇨🇭 CH

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a condition called Primary Biliary Cholangitis (PBC), confirmed using standard medical guidelines - You are currently being treated with a medication called seladelpar - You are willing and able to sign a form giving yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07556913 · Ipsen Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 31 January 2039

**Who might be able to join this trial:** - You took at least one dose of a medication called elafibranor either within three weeks before becoming pregnant or at any point during your pregnancy. - You previously took part in this program during an earlier pregnancy and took elafibranor around the time of or during tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646223 · Tampere University Hospital Phase 2 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 31 December 2032
🇫🇮 FI

**Who might be able to join this trial:** - Children between the ages of 6 and 15 years old - Able to swallow capsules - Already scheduled to have a diagnostic camera examination of the digestive tract at Tampere University - Has never previously been treated with oral vancomycin (a type of antibiotic) - Does not curre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07678645 · RenJi Hospital Phase 2 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 30 November 2027
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 70 years old (any gender). - You have been diagnosed with Atopic Dermatitis (a chronic skin condition causing itchy, inflamed skin) that has lasted more than 6 months, is present on both sides of the body, AND either you or a close family member has a histo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02137668 · Sacramento Pediatric Gastroenterology Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2018
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with primary sclerosing cholangitis (a liver and bile duct condition), biliary atresia (a bile duct condition present from birth), a long-term intestinal disorder, or you are scheduled to have a camera examination of your upper or lower digestive tract (en...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02931513 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇩🇰 DK

Who might be able to join this trial: - You have recently been diagnosed with Primary Biliary Cholangitis (a liver condition) - You have not yet been treated with a medication called UDCA (ursodeoxycholic acid) Who may not be able to join: - You are under 18 years of age - Your doctor expects you to live less than 6 m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03146910 · Fondazione Epatocentro Ticino Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇭 CH

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), based on recognised medical guidelines - You have certain specific antibodies in your blood related to PBC (called anti-mitochondrial antibodies and/or PBC-specific anti-nuclear antibodie...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03146936 · Fondazione Epatocentro Ticino Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇭 CH

Who might be able to join this trial: - You have been diagnosed with a liver condition called Primary Sclerosing Cholangitis (PSC) based on recognised medical guidelines, at any age. - You may also be eligible if you have been diagnosed with PSC by a specialist liver clinic, even if you don't fully meet the standard di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03175471 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2026
🇺🇸 US

Who might be able to join this trial: - You are between 6 and 23 years old. - You have been diagnosed with, or doctors suspect you may have, autoimmune hepatitis (AIH) or primary sclerosing cholangitis (PSC), which are conditions affecting the liver. Who may not be able to join: - You have previously had a liver trans...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03178630 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇺🇸 US

**Who might be able to join this trial:** - You are between 6 and 23 years old - You have been formally diagnosed with either autoimmune hepatitis (AIH) or primary sclerosing cholangitis (PSC), which are liver conditions where the immune system or bile ducts are affected (confirm with trial site) **Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03445585 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇺🇸 US

Who might be able to join this trial: - People diagnosed with a liver condition called PSC (Primary Sclerosing Cholangitis) who are between 18 and 85 years old at the time of joining the study. - People diagnosed with a liver condition called PBC (Primary Biliary Cholangitis) who are between 18 and 85 years old at the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03569826 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with Primary Biliary Cholangitis (a liver disease where the bile ducts are slowly destroyed) and/or Autoimmune Hepatitis (a condition where the immune system attacks the liver) Who may not be able to join: - You are under 18 years of age Important: Alway...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04181138 · Arbor Research Collaborative for Health Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 May 2029
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are between 2 and 25 years old at the time of screening. - You have been diagnosed with large duct PSC (a liver/bile duct condition), confirmed by a special imaging scan of the bile ducts showing certain abnormal patterns. - You have been diagnosed with small duct PSC, c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04514965 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with Primary Biliary Cholangitis (PBC) and your doctor has offered you treatment with a medicine called bezafibrate Who may not be able to join: - You are under 18 years old - Your life expectancy is estimated to be less than 6 months - You have been diag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04650243 · Peking Union Medical College Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Primary Biliary Cholangitis (PBC) based on recognised medical guidelines - You are 18 years old or older - Your PBC is at stage 2 or 3, meaning your liver function tests are abnormal and you are experiencing symptoms - After 6 to 12 months of trea...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04685200 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** **PSC Patients:** - People who are willing to follow all study procedures and are available for the full duration of the study - Men or women who are not pregnant, aged 18 or older - People who have been diagnosed with PSC (primary sclerosing cholangitis) confirmed by blood te...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04753996 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇺🇸 US

**Who might be able to join this trial:** - Adults with PSC (a liver condition called Primary Sclerosing Cholangitis) who are between 18 and 85 years old. - People whose PSC diagnosis has been confirmed through blood tests, imaging of the bile ducts, and/or a liver biopsy showing signs of the condition lasting at leas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05050136 · Mirum Pharmaceuticals, Inc. Phase 2 · 15 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇱 IL +7 more

Who might be able to join this trial: - You must be willing to sign a consent form and attend all required study visits from start to finish - You must be 18 years old or older at the time of your first screening appointment - You must have a confirmed diagnosis of Primary Biliary Cholangitis (PBC), a liver condition,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05151809 · University of Milano Bicocca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 January 2029
🇮🇹 IT

**Who might be able to join this trial:** - You are at least 18 years old and currently live in Italy - You have been diagnosed with Primary Biliary Cholangitis (PBC), which is confirmed by meeting at least 2 of the following 3 conditions: - Your blood tests show higher than normal levels of certain liver enzymes calle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05295680 · Aparna Goel Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called primary sclerosing cholangitis (PSC), confirmed by a liver biopsy and/or medical imaging scan - If you also have a bowel condition called inflammatory bowel disease (IBD), it must be currently well-controlled and stable, w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05618145 · University of Milano Bicocca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 October 2032
🇮🇹 IT

**Who might be able to join this trial:** - You are willing and able to agree to take part in the study before any study-related procedures begin - You have been diagnosed with a condition called Primary Sclerosing Cholangitis (PSC), confirmed according to the most up-to-date medical guidelines **Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05749822 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to give written consent to participate in the trial - You are between 18 and 75 years old - Your body mass index (BMI) is between 17 and 28 (a measure of weight relative to height) - You have been diagnosed with a liver condition called Primary Bilia...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05750498 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed by a doctor with autoimmune hepatitis (a condition where the immune system attacks the liver) - You have been diagnosed by a doctor with primary sclerosing cholangitis (a condition where the bile ducts in the liver become inflamed and scarred) - You have b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05751967 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign a consent form agreeing to take part in the study - You are between 18 and 75 years old - Your body mass index (BMI — a measure of weight relative to height) is between 17 and 28 - You have been diagnosed with a liver condition called Pri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05835505 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Primary Sclerosing Cholangitis (PSC) for at least 6 months, confirmed by a specific type of imaging scan of your bile ducts (confirm with trial site) - A liver enzyme called ALP (alkaline phosphatase) in your blood is higher than 1.5 times the no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05876182 · University of Milano Bicocca Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are willing and able to give your agreement to take part before any study procedures begin - You are male or a non-pregnant, non-breastfeeding female (including women who could become pregnant) between 15 and 70 years old - You have been diagnosed with a specific type of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05912387 · Stanford University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older of any gender - People with a confirmed diagnosis of PSC (a liver and bile duct condition), identified through specific imaging or a liver biopsy, who also have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) — for the main study...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05919433 · Hospital Mutua de Terrassa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇪🇸 ES

Who might be able to join this trial: - You have tested positive for certain liver-related antibodies in your blood (called AMA, anti-gp210, or anti-sp100) that have been recorded in the database of a participating hospital or clinic - You are 18 years of age or older Who may not be able to join: - You have been diagn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06197308 · University of Minnesota Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 76 years old - Your blood test shows that your bilirubin level (a measure of liver function) is not more than twice the upper limit of normal - A recent scan (within the last 6 months) has shown no blockage in your bile ducts and no signs of cancer - Y...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06286709 · University of Birmingham Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇬🇧 GB

Who might be able to join this trial: - People aged 18 or older who are able to give written consent and are willing and able to follow the trial's procedures. - People who have a confirmed diagnosis of inflammatory bowel disease (IBD) affecting the colon and are willing to have yearly colonoscopy checks as part of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06365424 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign and date a consent form agreeing to take part in the study - You must have previously taken part in the fenofibrate study for PBC (a specific earlier clinical trial, reference NCT02823353) - If you are a woman who could become pregnant, yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06443606 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are aged 18 or older but under 80 years old. - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of the following: abnormal liver enzyme levels (ALP), certain specific antibodies found in your blood, or a liv...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06455280 · Elizabeth C. Verna Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - You are able to give your own consent to participate in the study - You are 18 years old or older - You have been diagnosed with autoimmune hepatitis (AIH) and/or primary sclerosing cholangitis (PSC), which are liver conditions caused by the immune system - You are already on the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06675604 · Assistance Publique - Hôpitaux de Paris Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇪🇸 ES

**Who might be able to join this trial:** - You are between 18 and 70 years old and are on a waiting list for a liver transplant - You are waiting for a liver transplant mainly because of **decompensated cirrhosis** (when the liver has stopped working well enough and is causing serious symptoms), regardless of what ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06699121 · LISCure Biosciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition affecting the bile ducts, confirmed by imaging in line with standard medical guidelines - Your blood test shows a specific liver enzyme (ALP) is more th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06755151 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2035
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign a written consent form agreeing to take part in the study - You must have already completed a previous clinical trial for a liver condition called PBC (primary biliary cholangitis) that used a medication called fenofibrate (one of two spec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06755541 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2035
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign and date a consent form agreeing to take part in the study - You must have already completed a previous clinical trial studying fenofibrate for a liver condition called PBC (trial number NCT05751967) - If you are a woman who could become p...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06767605 · Asociación Española para el Estudio del Hígado Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇪🇸 ES

Who might be able to join this trial: - You have been officially diagnosed with one of the following liver conditions: Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), Primary Sclerosing Cholangitis (PSC), or a genetic (inherited) cholestatic (bile flow) disease (confirm with trial site) Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06825559 · Zydus Therapeutics Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old (inclusive) - Your body weight is in a healthy range for your height — specifically, your BMI is between 18.0 and 48.0 - You are able to swallow and keep down oral (by mouth) medication - You have a documented history of liver scarring (ci...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06864195 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇬🇧 GB

**Who might be able to join this trial:** - Men and women aged 18 or older - People who have been diagnosed with liver cancer (hepatocellular carcinoma or cholangiocarcinoma), confirmed by tissue sample or scan - People who have liver cirrhosis (scarring of the liver), confirmed by scan or tissue sample - People who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06905054 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are an adult between 18 and 75 years old (any gender) - You received a liver transplant for a condition called PSC (primary sclerosing cholangitis) or a liver cancer related to PSC, between 1 and 7 years before joining the study - You do not currently show signs of PSC re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07104201 · Xijing Hospital of Digestive Diseases Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 March 2035
🇨🇳 CN

**Who might be able to join this trial:** - You must have signed and dated a consent form agreeing to take part in the study - You must have already completed a previous clinical trial for a liver condition called PBC (primary biliary cholangitis) that used a medication called fenofibrate (trial reference NCT06591455)...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07149675 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a condition consistent with Primary Biliary Cholangitis (PBC), a liver disease - You are willing to take part and have given your consent, or a legal representative has given consent on your behalf (for example, if the patient has passed away or h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07161245 · Hospital Clinic of Barcelona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with Primary Biliary Cholangitis (PBC) according to recognised medical guidelines - You experience moderate to severe fatigue, measured by scoring 29 points or more on a specific PBC fatigue questionnaire called the P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07205874 · Hospital Universitario La Paz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇪🇸 ES

Who might be able to join this trial: - You are willing and able to sign a consent form agreeing to take part in the trial - Your blood test shows a positive result for a specific antibody called AMA, at a level of 1:40 or higher (confirm with trial site) - Your liver enzyme called ALP has consistently come back as nor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07216235 · Zydus Therapeutics Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2032
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand and sign a consent form and agree to follow the study rules - You have been taking a medication called ursodeoxycholic acid (UDCA) for at least 12 months at a stable dose for at least 6 months before the screening...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07229911 · Takeda Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 6 April 2028
🇺🇸 US

Who might be able to join this trial: **Phase 1a (Healthy Volunteer Phase):** - People who are willing and able to follow all trial rules and procedures, as judged by the trial doctor - People who have signed a consent form agreeing to take part before any trial procedures begin - People aged 18 to 68 years old at the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07282353 · Cascade Pharmaceuticals, Inc Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 9 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part in the study - People aged 18 to 75 years old (male or female) at the time of signing the consent form - People who have been diagnosed with primary biliary cholangitis (PBC) — a liver condition — based on...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07296458 · Xijing Hospital of Digestive Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and are able to understand and sign a consent form - You are aged 18 or older but under 75 years old - You have been diagnosed with primary biliary cholangitis (PBC) based on recognised medical guidelines, confirmed by at least two of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07304843 · Umecrine Cognition AB Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇩🇪 DE🇬🇷 GR🇭🇺 HU🇮🇹 IT🇷🇸 RS🇪🇸 ES Turkey (Türkiye)🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years of age or older (any gender) - You have been diagnosed with a liver condition called PBC (Primary Biliary Cholangitis), confirmed by at least 2 out of 3 key signs of the disease - You experience significant fatigue related to PBC, scoring 29 or above on a sp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07387549 · Ipsen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2031
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with primary sclerosing cholangitis (a liver condition affecting the bile ducts) based on standard medical tests and scans - Your liver disease is considered "compensated," meaning your liver is still functioning ade...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449793 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older, either male or female - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), based on specific medical guidelines from 2018 - You are currently taking a medication called UDCA (ursodeoxycholic acid) at a st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07598669 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇦🇹 AT

**Who might be able to join this trial:** - You must be over 18 years old. - You must have a confirmed diagnosis of primary biliary cholangitis (PBC), meaning at least two of the following three things apply to you: your liver enzyme levels (specifically alkaline phosphatase) have been higher than normal for at least 6...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07607353 · King's College Hospital NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver/bile duct condition, and have a severely narrowed bile duct (called a "high grade stricture") **Who may not be able to join:** - You have had a stent placed or a balloon procedure to open a bile duct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00059202 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 3 · 1 country Terminated
Terminated Phase 3 Est. completion 1 June 2008
🇺🇸 US

"Who might be able to join this trial: - You have had a long-term liver/bile duct condition (causing a build-up of bile) lasting at least 6 months. - Your blood test shows that a liver enzyme called alkaline phosphatase is at least one and a half times higher than the normal range. - Within the past year, you have had...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00550862 · Intercept Pharmaceuticals Phase 2 · 8 countries Terminated
Terminated Phase 2 Est. completion 1 August 2009
🇦🇹 AT🇨🇦 CA🇫🇷 FR🇩🇪 DE🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are between 18 and 70 years old (male or female). - You have been taking a stable dose of ursodeoxycholic acid (a liver medication) for at least 6 months before the screening visit. - If you are a woman, you are past menopause, have had surgery to prevent pregnancy, or are wi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00953615 · Mayo Clinic Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 May 2009
🇺🇸 US

Who might be able to join this trial: - You have been previously diagnosed with a condition called primary sclerosing cholangitis (PSC), confirmed through specific blood tests, imaging of the bile ducts, and a liver tissue sample - You are willing and able to sign a written consent form agreeing to take part in the stu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01142323 · University of Miami Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 December 2012
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) - You have been diagnosed with Primary Sclerosing Cholangitis (PSC), confirmed by imaging tests showing narrowing and widening of the bile ducts in or outside the liver - Your blood test shows a liver enzyme called alkaline...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02609048 · Gilead Sciences Phase 2 · 5 countries Terminated
Terminated Phase 2 Est. completion 1 July 2016
🇨🇦 CA🇩🇪 DE🇵🇱 PL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have given written consent to participate in the study, as required by local rules - You are between 18 and 75 years old (inclusive) - You have been diagnosed with Primary Biliary Cholangitis (PBC), confirmed by at least two of the following: abnormal liver enzyme levels...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02943447 · Gilead Sciences Phase 2 · 4 countries Terminated
Terminated Phase 2 Est. completion 4 September 2019
🇦🇹 AT🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: abnormal liver enzyme levels in your blood (ALP above normal), a positive blood test for certain antibodies (called AMA), or a liver biopsy sho...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03359174 · Yale University Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 December 2020
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old (male or female) - You have been diagnosed with a specific liver/bile duct condition called large-duct PSC (Primary Sclerosing Cholangitis), confirmed by imaging or biopsy, for at least 6 months - Your blood test results have shown a liver...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03394781 · Durect Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 31 January 2019
🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with primary sclerosing cholangitis (PSC) for at least 12 months, with or without a bowel condition called inflammatory bowel disease (IBD). - A specific liver enzyme in your blood (called alkaline phosphatase) is at least 1.5 times higher t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03742973 · Eli Lilly and Company Phase 2 · 2 countries Terminated
Terminated Phase 2 Est. completion 26 September 2019
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), confirmed by at least 2 of these 3 things: a history of elevated liver enzyme levels (ALP) for at least 6 months, a positive blood test for certain antibodies linked to PBC, or a liver b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04024813 · Gilead Sciences Phase 2 · 3 countries Terminated
Terminated Phase 2 Est. completion 9 January 2020
🇨🇦 CA🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with primary sclerosing cholangitis (PSC), confirmed by at least two of the following: a past blood test showing a raised liver enzyme called alkaline phosphatase, a liver biopsy that matches PSC, or a scan/procedure showing abnormal bile ducts consis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04060147 · Gilead Sciences Phase 1 · 1 country Terminated
Terminated Phase 1 Est. completion 2 September 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called Primary Sclerosing Cholangitis (PSC), confirmed through a special imaging scan of your bile ducts or a liver biopsy - You have evidence of liver scarring (cirrhosis), confirmed through a past liver biopsy, an abdominal sc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05642468 · Albireo, an Ipsen Company Phase 2 · 4 countries Terminated
Terminated Phase 2 Est. completion 10 July 2025
🇫🇷 FR🇮🇹 IT🇵🇱 PL🇪🇸 ES

**Who might be able to join this trial:** - Adults aged between 18 and 75 years old (inclusive) - People who have been diagnosed with large-duct primary sclerosing cholangitis (PSC), a liver condition involving scarring of the bile ducts, confirmed by at least 6 months of symptoms and specific imaging scans (MRCP or E...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Primary Biliary Cholangitis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Liver Foundation's national work on liver health also extends to primary biliary cholangitis.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.